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p < 0.05). The average 12-month costs per MDD patient were
substantially higher for severe vs. mild (mental health services:
$718 vs. $416; general medical services: $133 vs. $57; anti-
depressant usage $275 vs. $89). CONCLUSIONS: There was a
signiﬁcant association between depression severity and treatment
usage and costs, as well as between treatment adequacy and
severity.
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OBJECTIVES: To compare the direct health care costs, during
and after pregnancy, between women who continue their antide-
pressant therapy during the whole gestational period and those
who discontinue their treatment during the ﬁrst trimester.
METHODS: Data from a ‘Medications and Pregnancy’ registry
were used. Eligible women were 1) aged 15—45, 2) insured by
the Quebec drug plan for 12 months prior to, during preg-
nancy, and 3 months after pregnancy, 3) had 1 diagnoses of
psychiatric disorders before pregnancy, 4) used antidepressants
for 30 days in the year before pregnancy, and 5) had delivered.
Women who continued their antidepressant therapy throughout
pregnancy (Group 1) were compared to those who discontinued
during the ﬁrst trimester (Group 2). Health care costs, expressed
as mean total costs and cost ratios were determined during and
after pregnancy. RESULTS: In total, 2822 women met inclusion
criteria. Of these, 501 (17.8%) were in Group 1, and 676
(23.4%) in Group 2. The median number of days of antidepres-
sant use before pregnancy was higher in Group 1 (260 days vs.
144 days, p < .01); the proportion of women visiting a psychia-
trist was also higher in Group 1 (33.7% vs. 26.8%, p < .01). The
mean total cost during pregnancy in Groups 1 and 2 were
$2981.5 vs. $1842.9 (p < .01), and after pregnancy $1761.2 vs.
$1024.9 (p < .01). When prescription costs were excluded, these
differences in costs were no longer signiﬁcant. CONCLUSIONS:
Women who use antidepressants during pregnancy are likely to
have disorders of greater severity compared to those who discon-
tinue during the ﬁrst trimester. They incur signiﬁcantly greater
health care costs. However, this increased cost is attributable to
higher prescription costs.
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OBJECTIVES: British guidelines recommend escitalopram and
venlafaxine as second-line treatments in major depressive disor-
der (MDD). Clinical trials demonstrated similar efﬁcacy and
better tolerability of escitalopram vs. venlafaxine. To assess how
these results translate into real-life, this study compared second-
line treatment strategies with escitalopram or venlafaxine after
failure of ﬁrst-line generic SSRI, based on drug utilisation and
economic outcomes in patients with MDD in the UK.
METHODS: This cohort study using the General Practitioners
Research Database (GPRD) included adults with a diagnosis of
MDD, who had switched from a ﬁrst-line generic SSRI to esci-
talopram or venlafaxine between January 1, 2003 and June 30,
2005. A 6-month drug utilisation outcomes were dose-
adjustments, mean treatment duration (TD), and successful
treatment stop (no subsequent need for treatment) after switch.
6-month economic outcomes were health care resource use and
total health care costs, calculated by adding up unit costs
applied to resources. Appropriate multivariate models were
built, using propensity scoring to control on baseline character-
istics. RESULTS: A total of 535 patients were switched to esci-
talopram, 1284 to venlafaxine. In the escitalopram cohort
compared with the venlafaxine cohort, there were fewer males
(32% vs. 38%, p = 0.02) and patients had a shorter median
time to switch (50 vs. 59 days, p = 0.005). Fewer drug adjust-
ments were needed with escitalopram (27% vs. 44%, p <
0.001); consequently, a shorter second-line treatment duration
(106 vs. 123 days, p = 0.003), numerically more successful stops
(37% vs. 32%, p = 0.25), and fewer GP visits (12.3 vs 13.4
visits/patient, p = 0.06) were observed in escitalopram-treated
patients. 6-month total health care costs were signiﬁcantly
lower with escitalopram (£629 vs £749, p = 0.028), and were
similar in both cohorts without treatment costs (£567 vs. £589,
p = 0.73). CONCLUSIONS: After failure of a ﬁrst generic SSRI,
second-line treatment with escitalopram was associated with
easier management, shorter second-line treatment duration and
earlier success, with no increase in health care cost, compared
with venlafaxine.
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OBJECTIVES: In the UK, guidelines recommend generic selec-
tive serotonin reuptake inhibitors (SSRIs) as ﬁrst-line treatment,
and more expensive drugs such as escitalopram or venlafaxine
as second-line treatment for major depressive disorder (MDD).
However, clinical trials have shown that escitalopram is more
efﬁcacious than SSRIs and at least as efﬁcacious as venlafaxine
with better tolerability in severe MDD. The objective of this
study was to compare ﬁrst-line treatment with generic SSRIs,
escitalopram or venlafaxine based on 12-month health care uti-
lization and associated direct costs in patients with severe MDD
in the UK. METHODS: This cohort study using the General
Practitioners Research Database (GPRD) included adults with a
diagnosis of MDD classiﬁed as severe by published algorithm,
and a new prescription of generic SSRI, escitalopram or ven-
lafaxine between 2003 and 2005. Twelve-month resource use
was assessed; annual total health care cost was calculated by
adding-up unit costs for all health care resources and compared
between treatments using a generalized linear model; propensity
scoring was used to control for confounders and baseline costs.
RESULTS: A total of 1947 patients started with a generic SSRI,
323 with escitalopram and 215 with venlafaxine. No difference
in baseline characteristics was seen between groups. After treat-
ment start, hospitalizations were less frequent in escitalopram-
treated patients vs. SSRIs (0.1 vs. 0.2 hospitalization per
patient, p = 0.05) or venlafaxine (0.1 vs 0.3, p < 0.01). Total
health care cost for escitalopram was numerically lower than
for generic SSRIs (£916 vs £974, p = NS) and signiﬁcantly lower
than for venlafaxine (£916 vs £1367, p < 0.001), also when
excluding drug costs (escitalopram vs. SSRIs: £831 vs. £957, p
= 0.10; vs. venlafaxine: £831 vs. £1156, p = 0.01). CONCLU-
SIONS: In severe MDD, costs associated with ﬁrst-line escitalo-
pram were similar to generic SSRIs, but lower than with
venlafaxine, independently of drug costs. The main driver was
the lower frequency of hospitalization for escitalopram-treated
patients.
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